Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CDK2]
Substrate: MAPT

Description: Microtubule-associated protein tau (Neurofibrillary tangle protein)(Paired helical filament-tau) (PHF-tau).

Synonyms: MAPTL, MTBT1, TAU

Ensembl ID: ENSG00000186868

UniprotKB/SwissProt: TAU_HUMAN (P10636)

Function: Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm, cytosol. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton. Cell projection, axon. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of MAPT

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1MAPTTAU_HUMANS46AGLKE S PLQTP 29.35%PDK1 Swiss-Prot 55.0   ViewAnalyzing
2MAPTTAU_HUMANS46AGLKE S PLQTP 29.35%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
3MAPTTAU_HUMANT50ESPLQ T PTEDG 39.60%PDK1 Swiss-Prot 55.0   ViewAnalyzing
4MAPTTAU_HUMANT50ESPLQ T PTEDG 39.60%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
5MAPTTAU_HUMANT95AAQPH T EIPEG 42.15%CDC2 HPRD:01142(in vitro)  ViewAnalyzing
6MAPTTAU_HUMANT111AGIGD T PSLED 15.01% Swiss-Prot 55.0 (Similarity)View   
7MAPTTAU_HUMANT123AAGHV T QEPES 22.88%GSK3B HPRD:01142(in vitro;in vivo)  ViewAnalyzing
8MAPTTAU_HUMANT123AAGHV T QEPES 22.88%Erk2 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
9MAPTTAU_HUMANT123AAGHV T QEPES 22.88%p38g HPRD:01142(in vitro;in vivo)  ViewAnalyzing
10MAPTTAU_HUMANT123AAGHV T QEPES 22.88% HPRD:01142(in vitro)View   
11MAPTTAU_HUMANT173RQPSG T GPEDT 54.63%p38g HPRD:01142(in vitro)  ViewAnalyzing
12MAPTTAU_HUMANT173RQPSG T GPEDT 54.63%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
13MAPTTAU_HUMANT173RQPSG T GPEDT 54.63%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
14MAPTTAU_HUMANT173RQPSG T GPEDT 54.63%PKACa HPRD:01142(in vitro)  ViewAnalyzing
15MAPTTAU_HUMANS214KERPG S KEEVD 39.31%PKACa HPRD:01142(in vitro;in vivo)  ViewAnalyzing
16MAPTTAU_HUMANS214KERPG S KEEVD 39.31%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
17MAPTTAU_HUMANS214KERPG S KEEVD 39.31%CDK5 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
18MAPTTAU_HUMANS235QDSPP S KASPA 44.21%GSK3A HPRD:01142(in vitro)  ViewAnalyzing
19MAPTTAU_HUMANS235QDSPP S KASPA 44.21%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
20MAPTTAU_HUMANS235QDSPP S KASPA 44.21%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
21MAPTTAU_HUMANS235QDSPP S KASPA 44.21%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
22MAPTTAU_HUMANS238PPSKA S PAQDG 25.22% HPRD:01142(in vitro)View   
23MAPTTAU_HUMANS355DLPEP S EKQPA 56.62% HPRD:01142(in vitro)View   
24MAPTTAU_HUMANS396KKAKT S TRSSA 22.55%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
25MAPTTAU_HUMANS396KKAKT S TRSSA 22.55%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
26MAPTTAU_HUMANS400TSTRS S AKTLK 30.41%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
27MAPTTAU_HUMANT403RSSAK T LKNRP 42.56% HPRD:01142(in vitro)View   
28MAPTTAU_HUMANT470KTKIA T PRGAA 19.59%CDC2 HPRD:01142(in vitro)  ViewAnalyzing
29MAPTTAU_HUMANT470KTKIA T PRGAA 19.59%PDK1 Swiss-Prot 55.0   ViewAnalyzing
30MAPTTAU_HUMANT492RIPAK T PPAPK 36.29%Erk2 HPRD:01142(in vitro)  ViewAnalyzing
31MAPTTAU_HUMANT492RIPAK T PPAPK 36.29%PDK1 Swiss-Prot 55.0   ViewAnalyzing
32MAPTTAU_HUMANT498PPAPK T PPSSG 39.10%GSK3B HPRD:01142(in vitro;in vivo)  ViewAnalyzing
33MAPTTAU_HUMANT498PPAPK T PPSSG 39.10%PDK1 Swiss-Prot 55.0   ViewAnalyzing
34MAPTTAU_HUMANT498PPAPK T PPSSG 39.10%p38g HPRD:01142(in vitro;in vivo)  ViewAnalyzing
35MAPTTAU_HUMANT498PPAPK T PPSSG 39.10%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
36MAPTTAU_HUMANT498PPAPK T PPSSG 39.10%Erk2 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
37MAPTTAU_HUMANT498PPAPK T PPSSG 39.10%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
38MAPTTAU_HUMANS501PKTPP S SGEPP 52.78%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
39MAPTTAU_HUMANS512KSGDR S GYSSP 46.99%PKACa HPRD:01142(in vitro)  ViewAnalyzing
40MAPTTAU_HUMANS512KSGDR S GYSSP 46.99%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
41MAPTTAU_HUMANY514GDRSG Y SSPGS 13.76%TTBK1 Swiss-Prot 55.0   ViewAnalyzing
42MAPTTAU_HUMANS515DRSGY S SPGSP 33.31%PKACa HPRD:01142(in vitro;in vivo)  ViewAnalyzing
43MAPTTAU_HUMANS515DRSGY S SPGSP 33.31%TTBK1 Swiss-Prot 55.0   ViewAnalyzing
44MAPTTAU_HUMANS515DRSGY S SPGSP 33.31%PDK1 Swiss-Prot 55.0   ViewAnalyzing
45MAPTTAU_HUMANS515DRSGY S SPGSP 33.31%GSK3B HPRD:01142(in vitro;in vivo)  ViewAnalyzing
46MAPTTAU_HUMANS516RSGYS S PGSPG 25.46%PKACa HPRD:01142(in vitro)  ViewAnalyzing
47MAPTTAU_HUMANS516RSGYS S PGSPG 25.46%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
48MAPTTAU_HUMANS516RSGYS S PGSPG 25.46%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
49MAPTTAU_HUMANS516RSGYS S PGSPG 25.46%PDK1 Swiss-Prot 55.0   ViewAnalyzing
50MAPTTAU_HUMANS516RSGYS S PGSPG 25.46%TTBK1 Swiss-Prot 55.0   ViewAnalyzing
51MAPTTAU_HUMANS516RSGYS S PGSPG 25.46%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
52MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%GSK3B HPRD:01142(in vitro;in vivo)  ViewAnalyzing
53MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%TTBK1 Swiss-Prot 55.0   ViewAnalyzing
54MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%p38g HPRD:01142(in vitro;in vivo)  ViewAnalyzing
55MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%p38g HPRD:01142(in vivo)  ViewAnalyzing
56MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%GSK3B HPRD:01142(in vitro;in vivo)  ViewAnalyzing
57MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%p38g HPRD:01142(in vitro;in vivo)  ViewAnalyzing
58MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%GSK3B HPRD:01142(in vivo)  ViewAnalyzing
59MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
60MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%CDK5 HPRD:01142(in vivo)  ViewAnalyzing
61MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%CDK5 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
62MAPTTAU_HUMANS519YSSPG S PGTPG 24.44% HPRD:01142(in vivo)View   
63MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%Erk2 HPRD:01142(in vivo)  ViewAnalyzing
64MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%Erk2 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
65MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%CDK_group Phospho.ELM 7.0 ViewAnalyzing
66MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%PDK1 Swiss-Prot 55.0   ViewAnalyzing
67MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%CDK5 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
68MAPTTAU_HUMANS519YSSPG S PGTPG 24.44%Erk2 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
69MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%p38g HPRD:01142(in vitro)  ViewAnalyzing
70MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%CDK_group Phospho.ELM 7.0 ViewAnalyzing
71MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%PDK1 Swiss-Prot 55.0   ViewAnalyzing
72MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
73MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%CDK5 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
74MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
75MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
76MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
77MAPTTAU_HUMANT522PGSPG T PGSRS 28.06%PKACa HPRD:01142(in vitro;in vivo)  ViewAnalyzing
78MAPTTAU_HUMANS525PGTPG S RSRTP 28.43%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
79MAPTTAU_HUMANS527TPGSR S RTPSL 42.05% HPRD:01142(in vitro)View   
80MAPTTAU_HUMANT529GSRSR T PSLPT 20.62%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
81MAPTTAU_HUMANT529GSRSR T PSLPT 20.62%RSK2 HPRD:01142(in vitro)  ViewAnalyzing
82MAPTTAU_HUMANT529GSRSR T PSLPT 20.62%PKACa HPRD:01142(in vitro)  ViewAnalyzing
83MAPTTAU_HUMANT529GSRSR T PSLPT 20.62%CDK_group Phospho.ELM 7.0 ViewAnalyzing
84MAPTTAU_HUMANT529GSRSR T PSLPT 20.62%PDK1 Swiss-Prot 55.0   ViewAnalyzing
85MAPTTAU_HUMANT529GSRSR T PSLPT 20.62%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
86MAPTTAU_HUMANS531RSRTP S LPTPP 46.50%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
87MAPTTAU_HUMANS531RSRTP S LPTPP 46.50%PKA_group Phospho.ELM 7.0 ViewAnalyzing
88MAPTTAU_HUMANS531RSRTP S LPTPP 46.50%PKA_group Swiss-Prot 55.0  ViewAnalyzing
89MAPTTAU_HUMANS531RSRTP S LPTPP 46.50%CDK5 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
90MAPTTAU_HUMANS531RSRTP S LPTPP 46.50%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
91MAPTTAU_HUMANS531RSRTP S LPTPP 46.50%PKACa HPRD:01142(in vitro;in vivo)  ViewAnalyzing
92MAPTTAU_HUMANT534TPSLP T PPTRE 47.39%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
93MAPTTAU_HUMANT534TPSLP T PPTRE 47.39%CDK_group Phospho.ELM 7.0 ViewAnalyzing
94MAPTTAU_HUMANT534TPSLP T PPTRE 47.39%PDK1 Swiss-Prot 55.0   ViewAnalyzing
95MAPTTAU_HUMANT534TPSLP T PPTRE 47.39%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
96MAPTTAU_HUMANT534TPSLP T PPTRE 47.39%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
97MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%PDK1 Swiss-Prot 55.0   ViewAnalyzing
98MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%p38g HPRD:01142(in vitro)  ViewAnalyzing
99MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
100MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
101MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
102MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%CDK_group Phospho.ELM 7.0 ViewAnalyzing
103MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
104MAPTTAU_HUMANT548VAVVR T PPKSP 32.12%PKACa HPRD:01142(in vitro)  ViewAnalyzing
105MAPTTAU_HUMANS552RTPPK S PSSAK 35.47%CDK_group Phospho.ELM 7.0 ViewAnalyzing
106MAPTTAU_HUMANS552RTPPK S PSSAK 35.47%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
107MAPTTAU_HUMANS552RTPPK S PSSAK 35.47%PDK1 Swiss-Prot 55.0   ViewAnalyzing
108MAPTTAU_HUMANS554PPKSP S SAKSR 50.44% Swiss-Prot 55.0 View   
109MAPTTAU_HUMANS554PPKSP S SAKSR 50.44%PHKg1 HPRD:01142(in vitro)  ViewAnalyzing
110MAPTTAU_HUMANS555PKSPS S AKSRL 43.00% HPRD:01142(in vitro)View   
111MAPTTAU_HUMANS575LKNVK S KIGST 25.81%GSK3B(GSK3 beta) Phospho.ELM 7.0 ViewAnalyzing
112MAPTTAU_HUMANS575LKNVK S KIGST 25.81%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
113MAPTTAU_HUMANS579KSKIG S TENLK 35.70%PKCd HPRD:01142(in vitro)  ViewAnalyzing
114MAPTTAU_HUMANS579KSKIG S TENLK 35.70%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
115MAPTTAU_HUMANS579KSKIG S TENLK 35.70%CaMK2a HPRD:01142(in vitro)  ViewAnalyzing
116MAPTTAU_HUMANS579KSKIG S TENLK 35.70%PHKg1 HPRD:01142(in vitro)  ViewAnalyzing
117MAPTTAU_HUMANS579KSKIG S TENLK 35.70%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
118MAPTTAU_HUMANS579KSKIG S TENLK 35.70%GSK3B(GSK3 beta) Phospho.ELM 7.0 ViewAnalyzing
119MAPTTAU_HUMANS579KSKIG S TENLK 35.70%MARK1 Swiss-Prot 55.0   ViewAnalyzing
120MAPTTAU_HUMANS579KSKIG S TENLK 35.70%PKACa HPRD:01142(in vitro)  ViewAnalyzing
121MAPTTAU_HUMANS606LSNVQ S KCGSK 26.15%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
122MAPTTAU_HUMANS606LSNVQ S KCGSK 26.15%p38g HPRD:01142(in vitro;in vivo)  ViewAnalyzing
123MAPTTAU_HUMANS610QSKCG S KDNIK 46.43%MARK1(in PHF-tau) Swiss-Prot 55.0  ViewAnalyzing
124MAPTTAU_HUMANS610QSKCG S KDNIK 46.43%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
125MAPTTAU_HUMANS622VPGGG S VQIVY 17.70%MARK1(in PHF-tau) Swiss-Prot 55.0  ViewAnalyzing
126MAPTTAU_HUMANS622VPGGG S VQIVY 17.70%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
127MAPTTAU_HUMANS637LSKVT S KCGSL 29.01%p38g HPRD:01142(in vitro;in vivo)  ViewAnalyzing
128MAPTTAU_HUMANS637LSKVT S KCGSL 29.01%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
129MAPTTAU_HUMANS641TSKCG S LGNIH 42.44%GSK3A HPRD:01142(in vitro)  ViewAnalyzing
130MAPTTAU_HUMANS641TSKCG S LGNIH 42.44%MARK1(in PHF-tau) Swiss-Prot 55.0  ViewAnalyzing
131MAPTTAU_HUMANS641TSKCG S LGNIH 42.44%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
132MAPTTAU_HUMANS669KDRVQ S KIGSL 24.31%PKN1 HPRD:01142(in vitro;in vivo)  ViewAnalyzing
133MAPTTAU_HUMANS673QSKIG S LDNIT 35.70%MARK1(in PHF-tau) Swiss-Prot 55.0  ViewAnalyzing
134MAPTTAU_HUMANS673QSKIG S LDNIT 35.70%CaMK2a HPRD:01142(in vitro)  ViewAnalyzing
135MAPTTAU_HUMANS673QSKIG S LDNIT 35.70%PKACa HPRD:01142(in vitro)  ViewAnalyzing
136MAPTTAU_HUMANS673QSKIG S LDNIT 35.70%MARK1 HPRD:01142(in vitro)  ViewAnalyzing
137MAPTTAU_HUMANS673QSKIG S LDNIT 35.70%PKCd HPRD:01142(in vitro)  ViewAnalyzing
138MAPTTAU_HUMANT690NKKIE T HKLTF 27.99%CDK_group Phospho.ELM 7.0 ViewAnalyzing
139MAPTTAU_HUMANT690NKKIE T HKLTF 27.99%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
140MAPTTAU_HUMANY711GAEIV Y KSPVV 16.06%ABL1 HPRD:01142(in vivo)  ViewAnalyzing
141MAPTTAU_HUMANS713EIVYK S PVVSG 12.77%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
142MAPTTAU_HUMANS713EIVYK S PVVSG 12.77%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
143MAPTTAU_HUMANS713EIVYK S PVVSG 12.77%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
144MAPTTAU_HUMANS713EIVYK S PVVSG 12.77%PDK1 Swiss-Prot 55.0   ViewAnalyzing
145MAPTTAU_HUMANS713EIVYK S PVVSG 12.77%CDK_group Phospho.ELM 7.0 ViewAnalyzing
146MAPTTAU_HUMANS717KSPVV S GDTSP 31.05%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
147MAPTTAU_HUMANS717KSPVV S GDTSP 31.05% Swiss-Prot 55.0 (Similarity)View   
148MAPTTAU_HUMANT720VVSGD T SPRHL 44.12% HPRD:01142(in vitro)View   
149MAPTTAU_HUMANT720VVSGD T SPRHL 44.12% Swiss-Prot 55.0 View   
150MAPTTAU_HUMANS721VSGDT S PRHLS 25.36%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
151MAPTTAU_HUMANS721VSGDT S PRHLS 25.36%CDK_group Phospho.ELM 7.0 ViewAnalyzing
152MAPTTAU_HUMANS721VSGDT S PRHLS 25.36%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
153MAPTTAU_HUMANS721VSGDT S PRHLS 25.36%PDK1 Swiss-Prot 55.0   ViewAnalyzing
154MAPTTAU_HUMANS726SPRHL S NVSST 29.12% Swiss-Prot 55.0 (Similarity)View   
155MAPTTAU_HUMANS726SPRHL S NVSST 29.12%PKACa HPRD:01142(in vitro)  ViewAnalyzing
156MAPTTAU_HUMANS729HLSNV S STGSI 26.83% HPRD:01142(in vitro)View   
157MAPTTAU_HUMANS729HLSNV S STGSI 26.83% Swiss-Prot 55.0 (Similarity)View   
158MAPTTAU_HUMANS730LSNVS S TGSID 32.29%GSK3B HPRD:01142(in vitro)  ViewAnalyzing
159MAPTTAU_HUMANT731SNVSS T GSIDM 27.69% Swiss-Prot 55.0 (Similarity)View   
160MAPTTAU_HUMANS733VSSTG S IDMVD 18.59%TTBK1 Swiss-Prot 55.0   ViewAnalyzing
161MAPTTAU_HUMANS733VSSTG S IDMVD 18.59% HPRD:01142(in vitro)View   
162MAPTTAU_HUMANS733VSSTG S IDMVD 18.59%CaMK2_group Swiss-Prot 55.0  ViewAnalyzing
163MAPTTAU_HUMANS739IDMVD S PQLAT 11.79% HPRD:01142(in vitro)View   
164MAPTTAU_HUMANS739IDMVD S PQLAT 11.79%CDK5 HPRD:01142(in vitro)  ViewAnalyzing
165MAPTTAU_HUMANS739IDMVD S PQLAT 11.79%TTBK1 Swiss-Prot 55.0   ViewAnalyzing
166MAPTTAU_HUMANS739IDMVD S PQLAT 11.79%PDK1 Swiss-Prot 55.0   ViewAnalyzing
167MAPTTAU_HUMANT744SPQLA T LADEV 30.94%TTBK1 Swiss-Prot 55.0   ViewAnalyzing